Roche says MS drug candidate meets primary goal in late

FRANKFURT (Reuters) -Roche said on Monday that a late-stage trial testing its multiple sclerosis drug candidate fenebrutinib against the relapsing form of the disease achieved its primary goal.

Fenebrutinib was shown to significantly reduce the annualised relapse rate when compared with teriflunomide, also known as Aubagio, over a period of at least 96 weeks of treatment, the Swiss drugmaker said in a statement.

(Reporting by Ludwig Burger; Editing by Christian Schmollinger)